uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond

Qure achieved a 75% statistically significant slowing of Huntington's Disease progression with AMT-130 in a pivotal phase 1/2 ...
Oklahoma's News

Kaon and AMT Announce Strategic Partnership to Distribute TiVo Set-Top Boxes in North America

– Kaon, a leading provider of innovative digital solutions, and AMT, a prominent distributor of cutting-edge technology products, are pleased to announce their strategic partnership to distribute TiVo ...
TipRanks on MSN

uniQure price target raised to $65 from $30 at Stifel

Stifel raised the firm’s price target on uniQure (QURE) to $65 from $30 and keeps a Buy rating on the shares. The three-year AMT-130 data suggest a larger market opportunity and a higher probability ...
Nasdaq

FDA Agrees On Accelerated Approval Pathway For AMT-130 In Huntington's Disease; Stock Up 89%

(RTTNews) - Gene therapy company uniQure N.V. (QURE) announced Tuesday that the company reached agreement with the U.S. Food and Drug Administration (FDA) on key elements of an Accelerated Approval ...